4-MeO-MiPT
Discover related
3 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
| TripSit | Pharmacology | TiHKAL | ||
|---|---|---|---|---|
| Classification | ||||
| Class / category | — | — | ||
| Also known as | — | — | INDOLE, 3-[2-(ISOPROPYLMETHYLAMINO)ETHYL]-4-METHOXYN-ISOPROPYL-4-METHOXY-N-METHYLTRYPTAMINE3-[2-(ISOPROPYLMETHYLAMINO)ETHYL]-4-METHOXYINDOLE | |
| Safety | ||||
| Dose · Oral | ||||
| Common | 10–20 mg | — | 20–30 mg | ≠ |
| Duration | ||||
| Onset | 20–60 minutes | — | — | |
| Total | 3–7 hours | — | 4–6 hours | ≠ |
| After-effects | 1–4 hours | — | — | |
| Pharmacology | ||||
| Receptor activity | — | Diacylglycerol O-acyltransferase 1Unchecked | — | |
Dose at a glance
Each database's primary-route ladder on one shared scale — see where ranges line up or shift.
Duration at a glance
Total duration on one shared scale.
TripSit summary
A rare psychedelic tryptamine first synthesised by Alexander Shulgin, said to the be "little brother" of 5-MeO-MiPT. Said to be relatively mild with lighter visual effects than most tryptamines.
TiHKAL summary
The author regards this as a seemingly pivotal compound because it combines the orally favorable methyl/isopropyl nitrogen pattern with aromatic oxygenation, yet it is puzzlingly less potent than its 4-hydroxy and 5-methoxy relatives would lead one to expect. It is also frustratingly hard to make, and several related ring isomers remain untested in humans.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.